• Xing-Nong Ye, Xin-Ping Zhou, Ju-Ying Wei, Gai-Xiang Xu, Ying Li, Li-Ping Mao, Jian Huang, Yan-Ling Ren, Chen Mei, Jing-Han Wang, Yin-Jun Lou, Li-Ya Ma, Wen-Juan Yu, Li Ye, Li-Li Xie, Yin-Wan Luo, Chao Hu, Lin-Mei Niu, Min-Hua Dou, Jie Jin, and Hong-Yan Tong.
• a Institute of Hematology, Department of Hematology , The first Affiliated Hospital, College of Medicine, Zhejiang University , Hangzhou , PR China .
• Leuk. Lymphoma. 2016 Jan 1; 57 (6): 1311-8.

AbstractDecitabine (DAC) is commonly used for the treatment of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Previous studies have indicated DAC sequentially combined with idarubicin was an effective treatment for myeloid neoplasms. Therefore, a clinical study was conducted of the sequential combination of DAC followed by low-dose idarubicin/cytarabine in high-risk myeloid neoplasms. A total of 30 patients with a diagnosis of high-risk MDS, AML evolving from MDS or relapsed/refractory AML were enrolled in the study. DAC was administered 20 mg/m(2) daily for 3 consecutive days. Idarubicin (3 mg/m(2)/day) was administered 24 h after the last administration of DAC for 5-7 consecutive days, combined with cytarabine (30 mg/m(2)/day) for 7-14 days. The overall complete remission rate was 66.67%. The results demonstrate that epigenetic priming with decitabine followed by low-dose idarubicin/ytarabine has an increased anti-leukemia effect compared to traditional chemotherapy in high-risk myeloid neoplasms.

40 keywords...

hide…